AstraZeneca Competitors
| AZN Stock | USD 93.19 0.60 0.65% |
AstraZeneca PLC vs Amgen Correlation
Poor diversification
The correlation between AstraZeneca PLC ADR and AMGN is 0.75 (i.e., Poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding AstraZeneca PLC ADR and AMGN in the same portfolio, assuming nothing else is changed.
Moving together with AstraZeneca Stock
| 0.8 | JNJ | Johnson Johnson | PairCorr |
| 0.92 | MRK | Merck Company Earnings Call This Week | PairCorr |
| 0.74 | PFE | Pfizer Inc Earnings Call This Week | PairCorr |
Moving against AstraZeneca Stock
| 0.77 | NTNX | Nutanix | PairCorr |
| 0.62 | CPHI | China Pharma Holdings | PairCorr |
| 0.55 | SNOA | Sonoma Pharmaceuticals | PairCorr |
| 0.32 | KALA | Kala Pharmaceuticals | PairCorr |
AstraZeneca PLC Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between AstraZeneca PLC and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of AstraZeneca and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of AstraZeneca PLC ADR does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between AstraZeneca Stock performing well and AstraZeneca PLC Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze AstraZeneca PLC's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| NVS | 0.98 | 0.17 | 0.10 | 0.34 | 1.13 | 2.59 | 6.07 | |||
| GSK | 1.13 | 0.15 | 0.07 | 1.36 | 1.31 | 2.38 | 8.39 | |||
| RHHBY | 1.35 | 0.46 | 0.30 | 3.06 | 0.92 | 3.60 | 13.68 | |||
| BMY | 1.32 | 0.32 | 0.22 | 0.65 | 1.04 | 3.59 | 11.16 | |||
| SNY | 0.99 | (0.20) | 0.00 | (0.30) | 0.00 | 1.87 | 5.92 | |||
| MRK | 1.26 | 0.30 | 0.21 | 0.47 | 1.14 | 3.59 | 8.09 | |||
| GILD | 1.33 | 0.22 | 0.12 | 1.36 | 1.34 | 3.01 | 6.70 | |||
| JNJ | 0.80 | 0.26 | 0.24 | 4.88 | 0.59 | 2.29 | 5.56 | |||
| ABBV | 1.17 | (0.04) | 0.00 | (0.33) | 0.00 | 2.95 | 8.22 | |||
| LLY | 1.47 | 0.32 | 0.17 | 1.00 | 1.34 | 3.81 | 8.33 |
Cross Equities Net Income Analysis
Compare AstraZeneca PLC ADR and related stocks such as Novartis AG ADR, GlaxoSmithKline PLC ADR, and Roche Holding Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NVS | 4.4 B | 8.9 B | 9.3 B | 9.2 B | 10.2 B | 17.8 B | 6.7 B | 7.7 B | 12.6 B | 11.7 B | 8.1 B | 24 B | 7 B | 14.8 B | 11.9 B | 13.7 B | 9.9 B |
| GSK | 400 M | 5.3 B | 4.5 B | 5.4 B | 2.8 B | 8.4 B | 912 M | 1.5 B | 3.6 B | 4.6 B | 5.7 B | 4.4 B | 15 B | 4.9 B | 2.6 B | 3 B | 3.7 B |
| BMY | 1.1 B | 3.7 B | 2 B | 2.6 B | 2 B | 1.6 B | 4.5 B | 1 B | 4.9 B | 3.4 B | (9 B) | 7 B | 6.3 B | 8 B | (8.9 B) | (8.1 B) | (7.7 B) |
| SNY | 625 M | 5.6 B | 4.9 B | 3.7 B | 4.4 B | 4.3 B | 4.7 B | 8.4 B | 4.3 B | 2.8 B | 12.3 B | 6.2 B | 8.4 B | 5.4 B | 5.6 B | 6.4 B | 4.9 B |
| MRK | 539.9 M | 6.3 B | 6.2 B | 4.4 B | 11.9 B | 4.4 B | 3.9 B | 2.4 B | 6.2 B | 9.8 B | 7.1 B | 13 B | 14.5 B | 365 M | 17.1 B | 19.7 B | 20.7 B |
| GILD | (4 M) | 2.8 B | 2.6 B | 3.1 B | 12.1 B | 18.1 B | 13.5 B | 4.6 B | 5.5 B | 5.4 B | 123 M | 6.2 B | 4.6 B | 5.7 B | 480 M | 552 M | 524.4 M |
| JNJ | 613.7 M | 9.7 B | 10.9 B | 13.8 B | 16.3 B | 15.4 B | 16.5 B | 1.3 B | 15.3 B | 15.1 B | 14.7 B | 20.9 B | 17.9 B | 35.2 B | 14.1 B | 26.8 B | 28.1 B |
| ABBV | 4.6 B | 3.4 B | 5.3 B | 4.1 B | 1.8 B | 5.1 B | 6 B | 5.3 B | 5.7 B | 7.9 B | 4.6 B | 11.5 B | 11.8 B | 4.9 B | 4.3 B | 4.9 B | 6.2 B |
| LLY | 517.6 M | 4.3 B | 4.1 B | 4.7 B | 2.4 B | 2.4 B | 2.7 B | (204.1 M) | 3.2 B | 8.3 B | 6.2 B | 5.6 B | 6.2 B | 5.2 B | 10.6 B | 12.2 B | 12.8 B |
| PFE | 579.7 M | 8.7 B | 9.8 B | 11.6 B | 9.1 B | 7 B | 7.2 B | 21.3 B | 11.2 B | 16.3 B | 9.2 B | 22.1 B | 31.4 B | 2.1 B | 8 B | 9.2 B | 7.8 B |
| AMGN | 500 K | 3.7 B | 4.3 B | 5.1 B | 5.2 B | 6.9 B | 7.7 B | 2 B | 8.4 B | 7.8 B | 7.3 B | 5.9 B | 6.6 B | 6.7 B | 4.1 B | 4.7 B | 3.2 B |
AstraZeneca PLC ADR and related stocks such as Novartis AG ADR, GlaxoSmithKline PLC ADR, and Roche Holding Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in AstraZeneca PLC ADR financial statement analysis. It represents the amount of money remaining after all of AstraZeneca PLC ADR operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.AstraZeneca PLC Competitive Analysis
The better you understand AstraZeneca PLC competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, AstraZeneca PLC's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across AstraZeneca PLC's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
AstraZeneca PLC Competition Performance Charts
Five steps to successful analysis of AstraZeneca PLC Competition
AstraZeneca PLC's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by AstraZeneca PLC ADR in relation to its competition. AstraZeneca PLC's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of AstraZeneca PLC in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact AstraZeneca PLC's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to AstraZeneca PLC ADR, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your AstraZeneca PLC position
In addition to having AstraZeneca PLC in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Corporate Bonds Funds Thematic Idea Now
Corporate Bonds Funds
Funds or Etfs investing in different types of corporate debt instruments. The Corporate Bonds Funds theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Corporate Bonds Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out AstraZeneca PLC Correlation with its peers. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Will Pharmaceuticals sector continue expanding? Could AstraZeneca diversify its offerings? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every AstraZeneca PLC data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.78 | Dividend Share 3.13 | Earnings Share 3.01 | Revenue Per Share | Quarterly Revenue Growth 0.12 |
The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that AstraZeneca PLC's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether AstraZeneca PLC represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, AstraZeneca PLC's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.